Conversely, a 2022 pilot study investigating PD1 polymorphism in breast cancer patients found no association with PD1 (rs36084323) and particular breast cancer subtypes that included luminal A, luminal B, HER2 positive, and triple negative breast cancer [28]. This evidence concerns the gene ERBB2 and breast cancer.